A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat
NCT07140939
This study is recruiting at 6 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Subcutaneous Fat
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Last updated on ClinicalTrials.gov
- September 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Investigational site 1 · Encinitas, CA
Louisiana · 1
- Investigational site 4 · Baton Rouge, LA
Maryland · 1
- Investigational site 5 · Hunt Valley, MD
Nebraska · 1
- Investigational site 6 · Omaha, NE
New York · 1
- Investigational site 8 · New York, NY
Texas · 1
- Investigational site 11 · Pflugerville, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.